

Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"

Hale Toklu¹

¹ University of Central Florida

Potential competing interests: No potential competing interests to declare.

It looks like the increased mortality with tocilizumab could be a result of increased hepatic injury. Have the authors considered focusing on the type of hepatic injury or the characteristics of this injury? I think it is really valuable to explore the association and the mechanism further.

Is there a chance that you can expand the research? Add another year or collaborate with others to add more hospitals?